Hexagon Nutrition Share Price Today and Targets for 2026 to 2030

Hexagon Nutrition share price today

Most people searching hexagon nutrition share price arrive expecting a packaged-foods company and find something narrower. Hexagon Nutrition Limited, founded in 1991 and headquartered in Mumbai, makes micronutrient premixes, clinical nutrition and therapeutic food. Its customers include food companies that need fortification blends, and institutional buyers of ready-to-use therapeutic and supplementary food across Southeast Asia, the Middle East, Africa, Latin America and the Pacific. Yahoo Finance classifies it under Consumer Defensive, industry Packaged Foods, with 456 employees.

At the 10 September 2026 close the stock was around ₹68, giving a market capitalisation of roughly ₹830 crore. Trailing EPS was ₹1.98, which puts the shares near 34.3 times trailing earnings, and book value per share of ₹21.18 implies about 3.19 times book. The quote above updates after publication; every ratio and scenario input below stays fixed to that cut-off.

The tension in the name is easy to state and hard to resolve. Revenue grew 43.2% year on year and earnings grew 24.5%, which is the profile of a business finding demand, but the operating margin behind that growth is only 9.05%. The longer compounding record is genuinely disputed between the two sources this article uses, and that dispute gets its own section below. A thirty-four times multiple on a ₹830 crore company asks the recent year to be the new normal rather than a good year.

What Hexagon Nutrition actually sells

The company describes itself as a nutraceutical business built around the development and supply of micronutrient premixes, clinical nutrition and therapeutic food. That covers five fairly different commercial motions sitting on one formulation and manufacturing base.

Product family	What it is	Who buys it	Economic character
Micronutrient premixes	Vitamin and mineral blends dosed into food	Food companies and the nutraceutical industry	Business-to-business, recipe-embedded, sticky once qualified
Therapeutic and supplementary food	RUTF and RUSF for treating malnutrition	Institutional and international buyers	Tender-led, lumpy, price-competitive
Home fortification	Sachets and blends added at the point of consumption	Public and institutional nutrition programmes	Volume-driven, procurement-dependent
Health and wellness products	Functional foods, dietary supplements, plant-based alternatives	Consumer and specialist channels	Brand-sensitive, higher potential margin
Condition-specific formulations	Maternal, geriatric and lifestyle-disorder nutrition, including cardiovascular and obesity	Clinical and specialist channels	Slower to build, harder to displace

The premix line and the therapeutic-food line pull in opposite directions. Premixes are a specification business: once a blend is approved into a customer’s product, switching is inconvenient, and that supports retention. Ready-to-use therapeutic food is closer to a contract-manufacturing business sold into procurement processes, where volume can arrive in bursts and price is scrutinised. A single reported revenue line covers both, so a strong year does not by itself tell you which engine did the work.

The wellness and condition-specific ranges are the part of the mix that could change the economics, because branded nutrition earns more per rupee of revenue than tendered commodity volume. Whether that shift is actually happening is the central unanswered question in this name, and the disclosure captured at this cut-off does not settle it.

What the Hexagon Nutrition share price reflects today

The stock has been drifting up rather than re-rating. Between 5 August and 10 September 2026 the market capitalisation moved from about ₹789 crore to about ₹830 crore, and the distance from the 52-week high narrowed from about 15.8% to about 10.7%. In other words the market has been marking the shares up modestly, not repricing them violently in either direction, and nothing in the price action suggests an event the published record has not already absorbed.

Price marker	10 September 2026 reading	What it tells you
52-week high	₹76.16	Stock is about 10.71% below it
52-week low	₹50.66	Stock is roughly 34% above it
Shares outstanding	About 12.29 crore	Small float relative to most listed consumer names
Promoter holding	69.91%	Closely held, with limited free float

At this size one large order, one lost customer or one procurement cycle can move the reported numbers noticeably, and a modest trade can move the price. Both cut in both directions.

The financial record: what is available and what is not

One limitation has to be stated plainly before any of the analysis below is used. A full multi-year financial-statement table for Hexagon Nutrition was not captured at this cut-off. There are no year-by-year revenue, margin, profit and cash-flow rows to print, and no quarterly figures were captured either. This article therefore contains no quarterly-results section at all, and readers should treat that absence as missing data rather than as a comment on any particular quarter.

What is available is a trailing-twelve-month picture from Yahoo Finance dated 10 September 2026, plus two long-run growth rates and a return-on-capital figure carried in this site’s 5 August 2026 universe snapshot. That snapshot is Screener-derived, but it is not the same thing as a reading taken off the Screener page today, and the difference turns out to matter enough that the growth section below is built around it. What is here is enough to frame a valuation discussion and not enough to audit the trend inside it.

What is known	What it cannot tell you
Trailing revenue, EBITDA, margins, growth rates	How the year was shaped quarter by quarter
Trailing EPS, book value, P/E, price-to-book	Whether earnings included one-off items
Total debt, cash, debt-to-equity	Working-capital movement or receivable quality
Five-year sales and profit CAGR, ROCE	The path taken to get there, or whether the same rates still appear on the company’s own page
Promoter holding	Pledge levels or institutional ownership

Anyone who wants the year-by-year statements should read them directly from the company page on Screener.in and the NSE quote and filings page before relying on the framework in this article.

Trailing twelve months: fast revenue, thin operating margin

The most useful thing in the trailing numbers is a gap rather than a level. Earnings grew materially slower than revenue, so the additional sales arrived at lower incremental profitability or carried higher costs to win. That is what you would expect if tendered volume grew faster than branded volume, though the captured data cannot confirm the cause.

Trailing measure	Reading	Interpretation
Revenue	₹414 Cr	Small absolute base; percentage growth is easy to overweight
EBITDA	₹54 Cr	About 13% of revenue
Operating margin	9.05%	Thin for a nutrition brand, normal for a supply business
Profit margin	9.55%	Close to the operating margin
Revenue growth, year on year	43.2%	Well ahead of the long-run rate
Earnings growth, year on year	24.5%	Grew slower than sales
ROCE	22.55%	Capital efficiency is the strong point
Dividend yield	0.47%	The case rests on reinvestment, not income

The other pairing in that table worth holding side by side is the thin operating margin against the high return on capital. A company earning 22.5% on capital at a 9% operating margin is turning its assets over quickly rather than charging a premium price. That is a respectable model, and an unglamorous one. It is also a different model from the one a thirty-four times multiple normally implies, because asset turnover is far easier for a competitor to copy than pricing power is.

For comparison of what a high-margin consumer franchise looks like on the same metrics, the research on Hindustan Unilever and P&G Hygiene and Health is a useful reference point. Hexagon Nutrition is not that kind of business today.

The five-year growth record is disputed

Two sources disagree about how fast this company has compounded, and the gap is too large to paper over. The 5 August 2026 universe snapshot behind this site’s screening carries a five-year sales CAGR of 12.66% and a five-year profit CAGR of 12.31%. The company’s own page on Screener.in, read on 10 September 2026, shows compounded five-year growth of about 30% in sales and about 52% in profit. Those are not small measurement differences; they describe two different businesses.

The arithmetic on the Screener page explains most of it. That five-year window begins with the year to March 2021, when sales fell to roughly ₹86 crore from about ₹99 crore the year before. Compounding a pandemic-depressed base up to the ₹319 crore reported for the year to March 2026 reproduces the 30% figure almost exactly. Start one year earlier, from the ₹99 crore of March 2020, and the same series compounds at about 21% a year over six years instead. A growth rate measured off a trough is arithmetically correct and analytically misleading, which is the more likely reading here than an error in either source.

The two records are not describing an identical revenue base either. Yahoo Finance reports ₹414 crore of trailing revenue against the ₹319 crore the Screener page shows for the year to March 2026. A consolidation or period difference is the obvious candidate, but nothing captured at this cut-off settles it. The 22.55% ROCE quoted elsewhere here comes from the same 5 August snapshot and could not be re-verified against the company page on 10 September, so it should be treated as indicative rather than as a freshly confirmed reading.

What survives all of that is narrow and worth stating plainly. A 43% year in a ₹414 crore revenue base can come from one large contract cycle, a capacity addition, an export order pattern or a favourable procurement year. What it cannot do is prove a permanent change in the growth rate. And no published five-year rate here is clean enough to serve as the counterweight on its own: one is measured off a trough, the other could not be reproduced. A scenario framework therefore has to be built on a moderated number rather than on any single quoted rate, and the table further down splits that difference deliberately.

Balance sheet: modest debt and a small net cash position

Leverage is not where the risk sits in this name. The company holds more cash than borrowings, which at this size takes solvency off the list of things worth arguing about and leaves the argument where it belongs, on growth and price.

Balance-sheet item	10 September 2026	Why it matters
Total debt	₹33 Cr	Small in absolute terms
Total cash	₹55 Cr	Exceeds borrowings
Net cash	About ₹22 Cr	No solvency pressure at this size
Debt-to-equity	About 14%	Leverage is not the risk in this name

Fourteen percent debt-to-equity is low enough that the ratio is not a constraint on anything management wants to do. If the number is unfamiliar, the guide to the debt-to-equity ratio explains what it does and does not capture, particularly that it says nothing about working capital, which is usually the real cash pressure in a business that supplies food ingredients against institutional payment cycles.

What the balance sheet does not do is justify the multiple. Net cash of ₹22 crore against a market capitalisation of ₹830 crore is not a valuation support. It is simply the absence of a problem.

Valuation at the research cut-off

Valuation measure	10 September 2026 reading	Interpretation
Close	About ₹68	Fixed research input
Market capitalisation	About ₹830 Cr	Micro-cap band
Trailing EPS	₹1.98	Yahoo Finance trailing figure
Recalculated P/E	About 34.34×	Price divided by trailing EPS
Reported P/E	34.09×	Yahoo Finance trailing P/E
Book value per share	₹21.18	Price-to-book about 3.19×
ROCE	22.55%	The strongest single ratio here
Dividend yield	0.47%	Minimal

Thirty-four times trailing earnings is a growth-company multiple. It works if the trailing year’s 43.2% revenue growth marks a genuine step change in scale and the mix shifts toward higher-margin branded nutrition. It offers very little protection if growth settles back toward the low-teens rate the conservative five-year reading implies while the operating margin stays near nine percent, because in that case the earnings line grows slowly and the multiple has a long way to fall.

Two ratios are worth holding side by side. ROCE of 22.55% is genuinely good and argues that the capital already deployed is productive. A P/E of 34.34 argues that a lot of future capital will be deployed just as productively, at a growing scale, for years. Only the first of those is evidence. The guide to the P/E ratio formula sets out why a trailing multiple on a small, cyclical revenue base is a weaker signal than the same multiple on a steady one.

Valuation framework: growth has to earn the multiple

The scenario model starts with TTM EPS of ₹1.98. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹1. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. Dividends are excluded.

Scenario	Annual EPS growth	Exit P/E	Business interpretation
Bear	8%	20×	The strong year proves to be a cycle; growth drifts below even the conservative five-year reading and the multiple de-rates toward a supplier’s rating
Base	13%	28×	Growth settles near the conservative five-year reading of about 12% to 13%, margins hold near current levels, and the multiple compresses modestly
Bull	18%	38×	Branded and condition-specific nutrition lift mix, operating margin improves from 9%, and the market keeps paying a growth rating

The growth rates are anchored on the long-run record, not the trailing year, because one year is not a rate. The bear case sits below the conservative five-year reading, the base case sits on it, and even the bull case at 18% stays below the trailing year’s 24.5% earnings growth and far below the higher five-year reading. On multiples, the bear case sits well below today’s 34.34 times, the base case a little below it, and the bull case only modestly above. Assuming both the best growth outcome and a large permanent re-rating would simply restate today’s optimism in future-tense form. The method behind all of this is set out in how to value a stock.

Hexagon Nutrition share price target 2026 to 2030

The grid above is generated only from the three disclosed inputs: trailing EPS, an annual EPS growth rate and an exit P/E. It does not model a fresh share issue, an acquisition, a change in capital structure, currency translation on the export book, exceptional items, or the lumpiness that a tender-driven revenue line naturally carries. Nor does it weight the scenarios by probability. It should be re-derived from fresh inputs after the next set of published results, because a trailing-EPS model is only as current as the EPS inside it.

Risks that can break the case

The first risk is the one the numbers already show: the trailing year’s growth may not repeat, and the published five-year records are too far apart to say what the underlying rate is. Procurement cycles reverse, and a buyer who has just placed a large order does not place another one immediately. If revenue growth normalises while the multiple stays near thirty-four times, the arithmetic gets uncomfortable quickly.

The second is margin. An operating margin of 9.05% leaves little absorption room. Raw-material inflation in vitamins, minerals and protein inputs, freight costs on an export-heavy book, or price pressure in a competitive tender can each take a meaningful share of that margin, and earnings already grew slower than sales in the trailing year.

The third is customer and geography concentration. Exports run to Southeast Asia, the Middle East, Africa, Latin America and the Pacific, and therapeutic food is bought institutionally. That exposes the revenue line to aid and public health budgets, foreign-exchange movement, collection risk and political disruption in end markets, none of which the company controls.

The fourth is disclosure depth. With 69.91% held by promoters and a free float this small, the published record is thinner than a large-cap investor is used to. The missing multi-year statements and the unreconciled five-year growth rates are both illustrations of that, and thin disclosure raises the cost of being wrong on a stock that is also thin to trade.

The fifth is regulatory and quality risk. A business supplying nutrition into food products and clinical settings carries product-safety and certification exposure where a single failure damages customer qualification status far faster than it damages a quarter’s revenue.

What would change the picture

The case strengthens if revenue growth holds well above the low-teens rate for several consecutive periods rather than one, if the operating margin rises from 9.05% as the wellness and condition-specific ranges grow, and if ROCE stays near 22.5% while the business gets larger. Disclosure separating premix, therapeutic food and branded nutrition would materially improve confidence, because it would show which engine is actually growing.

It weakens if earnings keep growing slower than revenue, if margins compress under input or freight costs, if receivables stretch against institutional buyers, or if the trailing year turns out to have been a single procurement cycle. A quality or certification event would require reassessment independent of the financial model.

Monitoring scorecard

Question	Constructive evidence	Warning sign
Is the growth durable?	Several consecutive periods above the low-teens rate	Revenue reverts as one contract cycle ends
Is the mix improving?	Operating margin rises above 9.05%	Margin falls while revenue grows
Is capital still productive?	ROCE holds near 22.55% at larger scale	ROCE falls as the asset base expands
Is profit keeping pace?	Earnings growth matches or beats sales growth	The 24.5% versus 43.2% gap widens
Is the balance sheet stable?	Net cash maintained, debt-to-equity near 14%	Borrowing rises to fund working capital
Is disclosure improving?	Segment-level revenue and margin published	Reporting stays at a single consolidated line

Weighing the evidence at the cut-off price

Hexagon Nutrition is a genuinely interesting small business. It sits in an unglamorous part of the food chain, earns a high return on capital, carries more cash than debt, and has just delivered a sharply faster revenue year. Nothing in the captured data suggests financial fragility.

The difficulty is entirely in the price. At 34.34 times trailing earnings and 3.19 times book, the market is paying a growth multiple for a business whose long-run growth record two sources cannot agree on and whose operating margin is nine percent. The gap between those two facts is the whole investment question. Closing it requires the mix to shift toward branded, higher-margin nutrition and the growth to prove durable across more than one year. The evidence that would settle it, segment disclosure and a second and third strong period, is exactly what the record captured at this cut-off does not yet contain. Investors who want a closer parallel in the micro-cap ingredient-supplier space can compare the write-up on Vikram Thermo, another micro-cap supplier where a thin float and no research coverage shape the risk as much as the fundamentals do.

FAQ

What is the Hexagon Nutrition share price today?

The live quote appears in the widget at the top of this page and updates during market hours. For research purposes this article is fixed to the 10 September 2026 close of about ₹68, which implied a market capitalisation of roughly ₹830 crore. Every ratio below that opening section uses the same cut-off.

What is Hexagon Nutrition’s share price target for 2026?

The 2026 row of the scenario grid applies the trailing EPS of ₹1.98, an annual EPS growth rate and an exit P/E, scaled for the 112 days remaining in the calendar year from 10 September. Because only a fraction of the year remains, the 2026 figures move mainly with the assumed multiple rather than with the growth rate. They are illustrations of a method, not forecasts.

What is Hexagon Nutrition’s share price target for 2030?

The 2030 row compounds the same trailing EPS forward at each scenario’s growth rate and applies that scenario’s exit P/E. A four-year compounding horizon makes the outcome extremely sensitive to both inputs, which is why three scenarios are shown instead of one number. The range should be read as a span of possibilities under stated assumptions.

What does Hexagon Nutrition do?

It develops and supplies micronutrient premixes, clinical nutrition and therapeutic food, including ready-to-use therapeutic food, ready-to-use supplementary food and home-fortification products. It also makes functional foods, dietary supplements, plant-based nutritional alternatives, and maternal, geriatric and condition-specific formulations. It sells to food companies and the nutraceutical industry, and exports to Southeast Asia, the Middle East, Africa, Latin America and the Pacific.

Who are the promoters of Hexagon Nutrition?

Promoter holding was 69.91% at the 10 September 2026 reading, so the company is closely held and the free float is correspondingly small. The captured data does not include a promoter-wise breakdown or any pledge figure. Both are worth checking directly in the latest shareholding pattern filed with the exchange.

What are the key risks for Hexagon Nutrition’s stock?

The main risks are that the trailing year’s revenue surge does not repeat, that a 9.05% operating margin leaves little room to absorb input or freight cost increases, and that institutional and export demand is exposed to public-health budgets, currency movement and collection risk. The small free float, the limited depth of published financial detail and the unresolved disagreement between sources over the five-year growth record all add to the difficulty of assessing the business.

Related research

• Hindustan Unilever share price target
• P&G Hygiene and Health share price target
• Vikram Thermo share price target
• P/E ratio formula explained
• Debt-to-equity ratio explained
• How to value a stock

Sources and methodology

• Hexagon Nutrition on Screener.in
• Hexagon Nutrition quote and filings on NSE

The price, 52-week range, market capitalisation, shares outstanding, trailing EPS, book value, trailing P/E, price-to-book, dividend yield, total debt, total cash, debt-to-equity, trailing revenue, EBITDA, operating and profit margins, year-on-year revenue and earnings growth, employee count, promoter holding and the business description were captured from Yahoo Finance on 10 September 2026. The return on capital employed of 22.55%, the five-year sales and profit CAGRs of 12.66% and 12.31%, and the earlier market capitalisation of about ₹789 crore used to show how the price moved between the two dates all come from this site’s 5 August 2026 universe snapshot. That snapshot is Screener-derived, but it was not re-read off the Screener page for this article, and it should not be cited as a reading taken from that page. The competing five-year rates of about 30% and 52%, the ₹99 crore, ₹86 crore and ₹319 crore annual sales figures behind them, and the note that the two sources report different revenue for the latest year were read directly from the company page on Screener.in on 10 September 2026.

Analytical judgment begins after those figures. The choice of growth rates and exit multiples in the scenario table, the reading that earnings growing slower than revenue points to mix or cost pressure, the interpretation of a 22.55% ROCE against a 9.05% operating margin as an asset-turnover model, and the assessment of concentration, margin and disclosure risk are all interpretation, not reported data. Readers should verify current filings, shareholding patterns, liquidity and corporate actions on the exchange before relying on any of it.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.